Paris-Descartes University, Faculty of Medicine, APHP, European Georges Pompidou Hospital, Parasitology-Mycology Unit, Microbiology Department, Paris, France.
Int J Antimicrob Agents. 2017 Nov;50(5):617-621. doi: 10.1016/j.ijantimicag.2017.08.010. Epub 2017 Aug 9.
The order Mucorales, which includes the agents of mucormycosis, comprises a large number of species. These fungi are characterised by high-level resistance to most currently available antifungal drugs. Standardised antifungal susceptibility testing methods are now available, allowing a better understanding of the in vitro activity of antifungal drugs against members of Mucorales. Such tests have made apparent that antifungal susceptibility within this group may be species-specific. Experimental animal models of mucormycosis have also been developed and are of great importance in bridging the gap between in vitro results and clinical trials. Amphotericin B, posaconazole and isavuconazole are currently the most active agents against Mucorales; however, their activity remains suboptimal and new therapeutic strategies are needed. Combination therapy could be a promising approach to overcome resistance, but further studies are required to confirm its benefits and safety for patients.
被包括毛霉病病原体在内的毛霉目所包含的大量物种,具有高水平的耐药性,对目前大多数可用的抗真菌药物均耐药。目前已有标准化的抗真菌药敏检测方法,这有助于更好地了解抗真菌药物对毛霉目的体外活性。这些检测结果表明,该组的抗真菌敏感性可能具有种特异性。毛霉病的实验动物模型也已经开发出来,对于缩小体外结果和临床试验之间的差距非常重要。两性霉素 B、泊沙康唑和伊曲康唑是目前针对毛霉目最有效的药物;然而,它们的活性仍不理想,需要新的治疗策略。联合治疗可能是克服耐药性的一种有前途的方法,但需要进一步的研究来确认其对患者的益处和安全性。